Merck's KEYNOTE-057 bladder cancer trial ends with results posted; eight more registry updatesNov 13Weekly roundup, 9 itemsDaiichi SankyoMerck & Co., Inc.Updated
FDA accelerated approval for Enhertu in HER2-positive solid tumors, dated April 5, 2024Nov 9Regulatory decisionAmgenDaiichi Sankyo
Merck collaborator posts pancreatic cancer results; new MK-1045, COPD trial records surfaceNov 6Weekly roundup, 14 itemsDaiichi SankyoensifentrineUpdated
Enhertu wins EU approval for adjuvant HER2-positive early breast cancerOct 27Regulatory decisionAstraZenecaDaiichi Sankyo
Daiichi Sankyo registers Phase 3b T-DXd sequencing trial; posts RWE and access-program studiesOct 16Weekly roundup, 3 itemsAstraZenecaDaiichi Sankyo
Merck registers Phase 3 ovarian cancer and COPD trials; GT103/Keytruda NSCLC trial results postedOct 16Weekly roundup, 5 itemsDaiichi SankyoensifentrineUpdated
AstraZeneca, Daiichi Sankyo, Summit to test Datroway with ivonescimab comboOct 2PartnershipAstraZenecaDaiichi Sankyo
Merck registers Phase 3 V503 HPV vaccine trial in Chinese females previously given 2vHPV shotAug 28Weekly roundup, 4 itemsbevacizumabDaiichi Sankyo
Merck registers Phase 3 trial testing R-DXd maintenance in advanced ovarian cancerAug 20Trial updateDaiichi SankyoMerck & Co., Inc.
Merck registers Phase 3 ovarian cancer trial, plus Phase 1 study of MK-1406 in healthy adultsAug 3Weekly roundup, 2 itemsDaiichi SankyoMerck & Co., Inc.
AstraZeneca registers Phase III bladder cancer trial; joins Natera-led breast cancer studyJul 23Weekly roundup, 5 itemsAstraZenecaAZD6489
Merck completes MK-4082 obesity pill PK study; adds V132 vaccine and belzutifan pediatric trialsJul 17Weekly roundup, 8 itemsbelzutifanDaiichi Sankyo
AstraZeneca posts NATRON Phase III benralizumab results; registers ROSY-S anifrolumab rollover studyJul 10Weekly roundup, 9 itemsanifrolumab-fniaAstraZeneca